News Briefs: Global Med unveils disease management software
Global Med unveils disease management softwareGlobal Med, an application service provider focusing on medical IT and data management products, will launch DynaMetric, its new disease management software, at the National Managed Health Care Congress
Global Med unveils disease management software
Global Med, an application service provider focusing on medical IT and data management products, will launch DynaMetric, its new disease management software, at the National Managed Health Care Congress in Atlanta this month. DynaMetric tracks, collects, and compiles data on chronic diseases. Global Med of Lakewood, CO, says its first customer is a regional division of a large HMO, which plans to use the software initially to track a single chronic disease on a per-member per-month fee basis, and eventually to track up to 20 manageable chronic diseases. Global Med is providing the application through its wholly owned subsidiary, PeopleMed.com.
© 2000 Miller Freeman, Inc., a United News & Media company.
- Search again
- Homepage
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
